<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Knight Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/knight-therapeutics-inc</link>
<description>Latest news and press releases for Knight Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/knight-therapeutics-inc" rel="self" type="application/rss+xml" />
<item>
<title>Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/notice-of-knight-therapeutics-first-quarter-2026-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/notice-of-knight-therapeutics-first-quarter-2026-results-conference-call</guid>
<pubDate>Thu, 30 Apr 2026 11:30:00 GMT</pubDate>
<description>MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&#x201C;Knight&...</description>
</item>
<item>
<title>Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-to-present-at-the-2026-bloom-burton-and-co-healthcare-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-to-present-at-the-2026-bloom-burton-and-co-healthcare-investor-conference</guid>
<pubDate>Wed, 15 Apr 2026 11:30:00 GMT</pubDate>
<description>MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&#x201C;Knight&...</description>
</item>
<item>
<title>Knight Therapeutics Inc. ranks on The Globe and Mail's second annual Canada's Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-inc-ranks-on-the-globe-and-mails-second-annual-canadas-top-growing-women-led-companies-and-seventh-annual-women-lead-here-benchmark-of-executive-gender-diversity</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-inc-ranks-on-the-globe-and-mails-second-annual-canadas-top-growing-women-led-companies-and-seventh-annual-women-lead-here-benchmark-of-executive-gender-diversity</guid>
<pubDate>Fri, 27 Mar 2026 16:26:58 GMT</pubDate>
<description>MONTREAL, March 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&#x201C;Knight&...</description>
</item>
<item>
<title>Knight Amends Normal Course Issuer Bid</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-amends-normal-course-issuer-bid</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-amends-normal-course-issuer-bid</guid>
<pubDate>Mon, 23 Mar 2026 12:36:05 GMT</pubDate>
<description>MONTREAL, March 23, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (" Knight " or th...</description>
</item>
<item>
<title>Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-reports-fourth-quarter-and-year-end-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-reports-fourth-quarter-and-year-end-2025-results</guid>
<pubDate>Thu, 19 Mar 2026 11:30:00 GMT</pubDate>
<description>Delivered record-high revenues, Adjusted EBITDA 1 , Adjusted EBITDA per shar e 1 ...</description>
</item>
<item>
<title>Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-approval-of-additional-indication-for-minjuvir-tafasitamab-in-brazil</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-approval-of-additional-indication-for-minjuvir-tafasitamab-in-brazil</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ANVISA, the Brazilian health regulatory agency, for an additional indication for MINJUVI® (tafasitamab). The approval follows a supplemental regulatory filing and review by ANVISA under Project Orbis for MINJUVI®, in combination with rituximab and lenalid</description>
</item>
<item>
<title>Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-regulatory-supplemental-submission-of-minjuvir-tafasitamab-for-follicular-lymphoma-in-argentina-and-mexico</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-regulatory-supplemental-submission-of-minjuvir-tafasitamab-for-follicular-lymphoma-in-argentina-and-mexico</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication f</description>
</item>
<item>
<title>Knight Therapeutics Announces Approval of Additional Indication for MINJUVI&#xAE; (tafasitamab) in Brazil</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-approval-of-additional-indication-for-minjuviandxae-tafasitamab-in-brazil</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-approval-of-additional-indication-for-minjuviandxae-tafasitamab-in-brazil</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pa...</description>
</item>
<item>
<title>Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI&#xAE; (tafasitamab) for Follicular Lymphoma in Argentina and Mexico</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-regulatory-supplemental-submission-of-minjuviandxae-tafasitamab-for-follicular-lymphoma-in-argentina-and-mexico</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-regulatory-supplemental-submission-of-minjuviandxae-tafasitamab-for-follicular-lymphoma-in-argentina-and-mexico</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pa...</description>
</item>
<item>
<title>Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/notice-of-knight-therapeutics-fourth-quarter-and-year-end-2025-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/notice-of-knight-therapeutics-fourth-quarter-and-year-end-2025-results-conference-call</guid>
<pubDate>Thu, 12 Mar 2026 11:30:00 GMT</pubDate>
<description>MONTREAL, March 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&#x201C;Knight&...</description>
</item>
<item>
<title>Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-regulatory-submission-123000875</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-regulatory-submission-123000875</guid>
<pubDate>Wed, 18 Feb 2026 12:30:00 GMT</pubDate>
<description>MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for NIKTIMVO® (axatilimab) for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patie</description>
</item>
<item>
<title>Knight Therapeutics Announces Regulatory Submission of NIKTIMVO&#xAE; (Axatilimab) in Brazil</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-regulatory-submission-of-niktimvoandxae-axatilimab-in-brazil</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-regulatory-submission-of-niktimvoandxae-axatilimab-in-brazil</guid>
<pubDate>Wed, 18 Feb 2026 12:30:00 GMT</pubDate>
<description>MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan...</description>
</item>
<item>
<title>Knight Therapeutics Announces Health Canada Approval for WYNZORA&#xAE; to Treat Psoriasis Vulgaris</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-health-canada-approval-for-wynzoraandxae-to-treat-psoriasis-vulgaris</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-health-canada-approval-for-wynzoraandxae-to-treat-psoriasis-vulgaris</guid>
<pubDate>Thu, 18 Dec 2025 12:30:00 GMT</pubDate>
<description>MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan...</description>
</item>
<item>
<title>Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-health-canada-123000127</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-health-canada-123000127</guid>
<pubDate>Thu, 18 Dec 2025 12:30:00 GMT</pubDate>
<description>MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved WYNZORA®, a white uniform cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.1 Knight obtained the Canadian rights to WYNZORA® through</description>
</item>
<item>
<title>Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/profound-medical-regains-exclusive-distribution-rights-for-tulsa-pror-in-canada-from-knight</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/profound-medical-regains-exclusive-distribution-rights-for-tulsa-pror-in-canada-from-knight</guid>
<pubDate>Mon, 10 Nov 2025 21:30:00 GMT</pubDate>
<description>TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has regained exclusive distribution rights for TULSA-PRO® in Canada from Knight Therapeutics Inc. (“Knight”). The TULSA Procedure™, performed using the TULSA-PRO system</description>
</item>
<item>
<title>Knight Therapeutics Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-reports-third-quarter-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-reports-third-quarter-2025-results</guid>
<pubDate>Thu, 06 Nov 2025 12:30:00 GMT</pubDate>
<description>Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITD...</description>
</item>
<item>
<title>Knight Announces Closing of US$100 Million Revolving Credit Facility</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-announces-closing-of-usdollar100-million-revolving-credit-facility</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-announces-closing-of-usdollar100-million-revolving-credit-facility</guid>
<pubDate>Fri, 31 Oct 2025 21:15:00 GMT</pubDate>
<description>MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or &#x2...</description>
</item>
<item>
<title>Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-launch-of-jornay-pmtm-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-launch-of-jornay-pmtm-in-canada</guid>
<pubDate>Thu, 30 Oct 2025 21:15:00 GMT</pubDate>
<description>MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan...</description>
</item>
<item>
<title>Knight Therapeutics Announces Launch of JORNAY PM™ in Canada</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-launch-jornay-211500171</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/knight-therapeutics-announces-launch-jornay-211500171</guid>
<pubDate>Thu, 30 Oct 2025 21:15:00 GMT</pubDate>
<description>MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate HCI extended-release capsules) in Canada. JORNAY PM™ is an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children 6-12 years of age.1 “Effective ADHD management begins with helping children tran</description>
</item>
<item>
<title>Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call</title>
<link>https://6ix.com/company/knight-therapeutics-inc/news/notice-of-knight-therapeutics-third-quarter-2025-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/knight-therapeutics-inc/news/notice-of-knight-therapeutics-third-quarter-2025-results-conference-call</guid>
<pubDate>Thu, 30 Oct 2025 11:30:00 GMT</pubDate>
<description>MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&#x201C;Knight&#...</description>
</item>
</channel>
</rss>